Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer

Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Bone Diseases Bone Diseases, Metabolic Bone Loss Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Metabolic Diseases Musculoskeletal Diseases Neoplasms Neoplasms by Site Nutritional and Metabolic Diseases Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

40 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Urology Clinic & Prostate Centre, St. Joseph's Hospital, St. Joseph's Health Care London

London, Ontario, N6A 4V2, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men
Age of 40 years or greater
Diagnosis of advanced prostate cancer (ie: prostate-specific antigen [PSA] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone [LHRH] therapy)
Willing and able to consent

Exclusion criteria

Metastatic disease to bone
Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant)
Renal failure (serum creatinine > 200 umol/L)
Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis)
Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty)
Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial
Gastrointestinal (GI) pathology (eg. malabsorption syndrome)
Parathyroid disease

Sponsors and collaborators

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Other

Collaborators

Lawson Health Research Institute Internal Review Fund
University of Western Ontario, Canada

Registry information

Important dates

Study start: 2005
Primary completion: 2008
Study completion: 2008
First posted: Sep 20, 2005
Registry last updated: Jul 29, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed